Human kallikrein 13 protein in ovarian cancer cytosols: A new favorable prognostic marker

Andreas Scorilas, Carla A. Borgoño, Nadia Harbeck, Julia Dorn, Barbara Schmalfeldt, Manfred Schmitt, Eleftherios P. Diamandis

Publikation: Beitrag in FachzeitschriftArtikelBegutachtung

68 Zitate (Scopus)

Abstract

Purpose: Human kallikrein 13 (hK13; encoded by the KLK13 gene) is a secreted serine protease expressed in endocrine tissues, including the prostate, testis, breast, and ovary. We have previously reported steroid hormone regulation of the KLK13 gene and its clinical value as a marker of favorable prognosis in breast cancer at the mRNA level. We hypothesized that hK13 may represent a potential biomarker for ovarian carcinomas. Patients and Methods: Using a newly developed enzyme-linked immunosorbent assay (ELISA), hK13 levels were quantified in 131 ovarian tumor extracts and correlated with various clinicopathological variables and outcome (progression-free survival [PFS], overall survival [OS]), over a median follow-up period of 42 months. Results: hK13 concentration in ovarian tumor cytosols ranged from 0 to 18.4 ng/mg of total protein. An optimal cutoff value of 0.13 ng/mg (67th percentile) was selected, based on the ability of hK13 values to predict the PFS of the study population, to categorize tumors as hK13-positive or negative. Women with hK13-positive tumors most often had early stage (stage I/II) disease, no residual tumor after surgery and optimal debulking success (P < .05). Univariate and multivariate Cox regression analyses revealed that patients with hK13-positive tumors had a significantly longer PFS and OS than hK13-negative patients (P < .05). Kaplan-Meier survival curves further confirmed a reduced risk of relapse and death in women with hK13-positive tumors (P = .007 and P = .002, respectively). Conclusion: These results indicate that hK13 is an independent marker of favorable prognosis in ovarian cancer.

OriginalspracheEnglisch
Seiten (von - bis)678-685
Seitenumfang8
FachzeitschriftJournal of Clinical Oncology
Jahrgang22
Ausgabenummer4
DOIs
PublikationsstatusVeröffentlicht - 2004
Extern publiziertJa

Fingerprint

Untersuchen Sie die Forschungsthemen von „Human kallikrein 13 protein in ovarian cancer cytosols: A new favorable prognostic marker“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren